Faculty Profile

Dr. John M. Kane, M.D.

John M. Kane, M.D.

Adjunct Clinical Professor, Department of Psychiatry and Behavioral Sciences

Adjunct Clinical Professor, The Saul R. Korey Department of Neurology

Chair, Department of Psychiatry at North Shore University Hospital and Long Island Jewish Medical Center, Department of Psychiatry and Behavioral Sciences

Professional Interests

John M. Kane, MD is Vice President for Behavioral Health Services of the North Shore - Long Island Jewish Health System and Chairman of Psychiatry at The Zucker Hillside Hospital. He is Chairman of Psychiatry and Professor of Psychiatry and Molecular Medicine at the Hofstra North Shore-LIJ School of Medicine.  Dr. Kane received his B.A. from Cornell University and his M.D. from the New York University School of Medicine.  He currently directs the NIMH-funded Advanced Center for Interventions and Services Research in Schizophrenia at The Zucker Hillside Hospital. He has been a member of the Board of Scientific Counselors for NIMH, and he has served on the council of the American College of Neuropsychopharmacology. He has chaired the NIMH Psychopathology and Psychobiology Review Committee as well as the Psychopharmacologic Drugs Advisory Committee of the Food and Drug Administration. 

Dr. Kane is a schizophrenia researcher with extensive experience in intervention and services research. He directs an NIMH-funded Advanced Center for Services and Interventions Research that has provided an infrastructure for many of these efforts. For over 30 years, Dr. Kane has been an international leader in the field of schizophrenia research. His work has focused on improving the early diagnosis and treatment of this illness, as well as developing new treatments and treatment strategies to improve its long-term course and outcome. He was a pioneer in the study of first episode schizophrenia and also conducted groundbreaking work with clozapine for treatment resistant schizophrenia. He has continuously focused on both therapeutic and adverse effects of psychotropic drugs, thereby informing benefit-to-risk considerations. Dr. Kane has always been on the forefront of bringing the next generation of medicines to patients in order to enhance long-term effectiveness and quality of life. His research program is also committed to utilizing new technologies that can enhance access, quality of care and outcomes while increasing cost effectiveness.

Dr. Kane also devotes his efforts to standardizing the outcome measurements employed in psychiatric research and helping to ensure the translation of research into clinical practice. He and his colleagues have helped to determine treatment strategies for all phases and subtypes of schizophrenia. His findings have been circulated worldwide and have become part of the fabric of modern care.

Dr. Kane is a recipient of the Arthur P. Noyes Award in Schizophrenia, the NAPPH Presidential Award for Research, the American Psychiatric Association Foundations' Fund Prize for Research, the Kempf Fund Award for Research Development in Psychobiological Psychiatry, the Lieber Prize for Outstanding Research in Schizophrenia, the Heinz E. Lehmann Research Award from New York State, and the Dean Award from the American College of Psychiatrists.

Material in this section is provided by individual faculty members who are solely responsible for its accuracy and content.

The Zucker Hillside Hospital
75-59 263rd Street
Glen Oaks, NY 11004

Tel: 718.470.8141
Fax: 718.343.7739

Research Information